1. NoAb Biodiscoveries' largest research project is centred around DTEx™, a microarray-based technology for profiling the effects of drugs on the gene expression of key proteins involved in drug distribution and disposition. The objective was to develop a tool to give drug developers early indications of the effects and interactions of drug candidates.
We developed a microarray containing the genes for all 48 ATP Binding Cassette (ABC) transporters. The next step was to test the effects of certain drugs on induction or suppression of these genes in various cell lines. We then developed a larger microarray, including the genes for uptake drug transporters, Phase I and II metabolic enzymes and nuclear receptors, to give a wider picture of the drug’s effects on all of the proteins involved in drug disposition.
We are now beginning to offer DTEx™ as a service to pharmaceutical developers while expanding its use in a wider variety of biological systems.
2. Through a collaboration with the University of Waterloo, NoAb is developing a new technology for sampling drug candidates In Vivo.
3. NoAb BioDiscoveries continues to develop unique models to study brain penetration and localization of drug candidates. We have now fully validated our model for serial CSF and plasma collection In Vivo, and are well on our way to validating our Microdialysis model.
